Evaxion A/S (EVAX) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Evaxion A/S (EVAX).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $2.85

Daily Change: +$0.02 / 0.70%

Daily Range: $2.75 - $2.98

Market Cap: $18,507,550

Daily Volume: 108,235

Performance Metrics

1 Week: 9.33%

1 Month: 15.35%

3 Months: 97.97%

6 Months: -2.01%

1 Year: -76.56%

YTD: -30.68%

Company Details

Employees: 46

Sector: Health technology

Industry: Biotechnology

Country:

Details

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Selected stocks

Globa Terra Acquisition Corporation (GTERU)

BEST SPAC I Acquisition Corp. (BSAAU)

Cre8 Enterprise Limited (CRE)